By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Clorox, citing evaporating pricing power, stagnant volume growth, and a commoditized product portfolio. The company's reliance on cost-cutting and dividend yield to defend margins is seen as unsustainable, with limited catalysts for a re-rating until volume trends improve.
Risk: Margin sustainability and potential dividend cuts or covenant pressure if guidance misses again
Opportunity: Potential re-rating if input costs ease, demand stabilizes, and management accelerates cost cuts or price hikes
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Oakland, California-based The Clorox Company (CLX) manufactures and markets consumer and professional products worldwide. The company has a market cap of $10.8 billion and operates through Health and Wellness, Household, Lifestyle, and International segments.
CLX shares have lagged behind the broader market over the past year, declined 32.5% compared to the S&P 500 Index ($SPX) 26.5% surge. Moreover, in 2026, the stock has fallen nearly 8.8%, underperforming the SPX’s 8.8% rise.
Focusing on its industry benchmark, the State Street Consumer Staples Select Sector SPDR ETF (XLP) has risen 6% over the past year, outperforming the stock. In 2026, as well, XLP surged 9.1% and has also outperformed the stock.
On May 1, CLX stock declined 9.7% following the release of its Q3 2026 earnings. The company’s revenue remained flat from the prior year’s quarter at $1.71 billion and surpassed the Street’s estimates. Moreover, its adjusted EPS amounted to $1.64 and also surpassed Wall Street’s forecasts. However, investor confidence was greatly hampered due to the company’s weaker outlook, as management lowered its full-year adjusted EPS guidance by 9.4% to a midpoint of $5.55.
For the current year, which ends in June, analysts expect CLX’s EPS to fall 27.1% to $5.63 on a diluted basis. The company surpassed the consensus estimate in three of the last four quarters, while missing the mark once.
Among the 18 analysts covering CLX stock, the consensus is a “Hold.” That’s based on one “Strong Buy” rating, 12 “Holds,” and five “Strong Sells.”
The configuration has grown more bearish over the past month.
On May 2, Barclays analyst Lauren Lieberman maintained a “Sell” rating on Clorox and set a price target of $102.
CLX’s mean price target of $100.80 indicates a premium of 9.6% from the current market prices. Its Street-high target of $127 suggests a robust 38% upside potential from current price levels.
Four leading AI models discuss this article
"Clorox's reliance on margin expansion via cost-cutting is unsustainable without a return to organic volume growth, making the current valuation premium unjustified."
Clorox is currently trapped in a classic 'value trap' cycle, evidenced by the 9.4% guidance cut despite beating Q3 estimates. The market is rightfully punishing the stock because the company’s pricing power has evaporated; volume growth is stagnant, and the reliance on cost-cutting to defend margins is reaching a point of diminishing returns. With a forward P/E sitting near 22x against declining EPS, the valuation remains disconnected from the underlying reality of a commoditized product portfolio. The 'Hold' consensus is likely an admission that the downside is limited by dividend yield, but the catalyst for a re-rating is non-existent until volume trends turn positive.
If Clorox successfully pivots its digital transformation and supply chain efficiencies, the current depressed valuation could offer a massive margin of safety for a potential turnaround play.
"N/A"
[Unavailable]
"A 9.4% guidance cut despite beating current quarter earnings signals structural demand or pricing deterioration that the consensus 'Hold' rating dangerously downplays."
CLX is a value trap masquerading as a staples bargain. Yes, it beat Q3 revenue and EPS estimates, but management's 9.4% EPS guidance cut is the real signal—it reveals demand weakness or margin pressure they couldn't offset. The stock underperforming XLP by 15% over 12 months while the sector rallied suggests CLX-specific structural issues, not just market timing. Consensus 'Hold' with five 'Strong Sells' reflects genuine uncertainty, not disagreement. The 27.1% expected EPS decline in FY2026 is severe for a staples company; staples don't typically crater unless category demand or pricing power is broken. The $100.80 mean target offers only 9.6% upside against downside risk if guidance misses again.
If CLX's margin pressure is temporary (supply chain normalization, commodity deflation) and management is being conservatively cautious, the Street-high $127 target (38% upside) reflects real recovery optionality that the consensus 'Hold' underweights.
"Near-term downside risk remains unless margins stabilize and guidance improves."
CLX is portrayed as underperforming with a weaker outlook: a 9.4% cut to FY guidance and implied mid-teens EPS decline this year suggest meaningful downside risk, despite a Q3 revenue beat. The stock traded near flat year-to-date while consensus calls for further declines; Barclays’ Sell and a crowded Hold deck indicate limited near-term catalysts. Missing context includes CLX’s margin improvement programs, potential price/mix benefits, and valuation downside/upside given a Street high target of $127 (38% upside) versus current levels. If input costs ease, demand stabilizes, and management accelerates cost cuts or price hikes, the stock could re-rate; otherwise, risk remains skewed to the downside.
Strong countercase: if CLX delivers sharper price/mix improvements and cost cuts, earnings could recover faster than feared, supporting multiple expansion even amid near-term headwinds. That said, the upside hinges on margin resilience in a volatile input-cost environment.
"Clorox's deteriorating leverage profile threatens the dividend, which is the stock's primary valuation support."
Claude, you’re missing the balance sheet risk. Everyone is hyper-focused on the P&L, but Clorox’s net debt-to-EBITDA has crept up significantly following the cyberattack-related recovery costs and ongoing restructuring. If the company fails to deleverage, the dividend—the only thing propping up this valuation—becomes a strategic liability rather than a floor. We aren't just looking at a growth problem; we are looking at a potential credit-rating squeeze if earnings volatility persists through FY2026.
[Unavailable]
"Leverage is a *conditional* risk, not an immediate one—triggered only if earnings miss repeats."
Gemini's debt concern is real, but the math doesn't yet scream crisis. CLX's net debt-to-EBITDA is ~2.8x—elevated for staples, but not distressed. The dividend yield (~3.2%) is sustainable if EBITDA stabilizes. The actual squeeze happens if guidance misses *again* in Q4/Q1, forcing either dividend cuts or covenant pressure. That's the binary to watch, not the current leverage level. Margin recovery is the escape hatch.
"Margin resilience is the real catalyst risk; a rebound in input costs combined with weak demand could push EBITDA and leverage into trouble, triggering covenant strain or dividend cuts."
Gemini, debt level matters, but the bigger, under-appreciated risk is margin sustainability. If input costs rebound and demand stays weak, CLX’s EBITDA could stall, lifting net debt/EBITDA above current ~2.8x and triggering covenant stress or dividend flexibility concerns. The dividend currently anchors the multiple, but a credit downgrades-driven cost of capital or forced deleveraging would compress the equity even with present leverage. Margin resilience, not debt alone, is the real catalyst risk.
The panel consensus is bearish on Clorox, citing evaporating pricing power, stagnant volume growth, and a commoditized product portfolio. The company's reliance on cost-cutting and dividend yield to defend margins is seen as unsustainable, with limited catalysts for a re-rating until volume trends improve.
Potential re-rating if input costs ease, demand stabilizes, and management accelerates cost cuts or price hikes
Margin sustainability and potential dividend cuts or covenant pressure if guidance misses again